Elevated homocysteine (Hey) levels are observed in two apparently unrelated diseases: neural-tube defects (NTD) and premature vascular disease. Defective human methionine synthase (MS) could result in elevated Hey levels. We sequenced the coding region of MS in 8 hyperhomocysteinaemic patients (4 NTD patients and 4 patients with preg nancies complicated by spiral arterial disease, SAD). We identified only one mutation resulting in an amino acid substitution: an A->G transition at bp 2756, converting an aspartic acid (D919) into a glycine (C). We screened genomic DNA for the presence of this mutation in 56 NTD patients, 69 mothers of children with NTD, 108 SAD patients and 364 controls. There was no increased preval ence of the G G and AG genotypes in NTD patients, their mothers or SAD patients. The D919G mutation does not seem to be a risk factor for NTD or vascular disease. We then examined the mean Hey levels for each MS genotype. There was no correlation between GG-or AG-genotype and Hey levels. The D919G mutation is thus a fairly prevalent, and prob ably benign polymorphism. This study, though lim ited, provides no evidence for a major involvement of MS in the aetiology of homocysteine-related dis eases such as NTD or vascular disease.
Introduction
Two apparently unrelated diseases, neural-tube defects (NTDs) and premature vascular disease, are both associated with moderately elevated homocyst eine (Hey) levels.1' 3 Enzymes and cofactors involved in Hey metabolism are currently being investigated for their contribution to these diseases. Hey is a braneh-point metabolite of methionine metabolism, and can be remethylated to methionine or catabolized in the transsulphuration pathway to cysteine, (Figure 1) .
NTDs account for a significant part of present-day perinatal morbidity and mortality. Several studies showed that perieonceptional folate administration reduces the occurrence and recurrence risk of N TD s.4'5 W e have postulated that heterozygosity for cystathionine /?-synthase (CS) deficiency could be a cause of moderate hyperhomocysteinaemia in NTD, but w e have not found evidence for a defective CS in mothers of children with NTD. 1 5,1O-Methylenetetrahydrofolate reductase (M TH FR) is one of the key enzymes in the folatedependent remethylation of Hey to methionine. W e recently showed that homozygosity for the 677C-*T mutation in the M TH FR gene, causing thermolability of the enzyme,6"8 can partly explain the observed elevated H ey levels in NTD, and this has recently been confirmed by others.9,10 The 677C->T mutation in the M T H FR gene is the first identified genetic risk factor for NTD. However, even after exclusion of individuals homozygous for the 677C-*T mutation in M TH FR, w e still observe significantly elevated Hey levels in N TD patients and their parents.11 So, in addition to the 677C->T mutation in MTHFR, other mutations in genes affecting the conversion of Hey to methionine could be present in these families.
In most Western countries, vascular disease is one of the main causes of death. Along with high blood pressure and cholesterol, increased plasma Hey level is a risk factor for vascular disease, with a relative risk comparable to hypercholesterolaemia.3 It has been postulated that the elevation of Hey levels in patients with vascular disease could be caused by heterozygosity for CS.12,13 However, we have not found any evidence for involvement of CS deficiency in vascular disease,14 The 677C-^T mutation in the M T H FR gene, resulting in elevated Hey levels, can only partly explain the elevated Hey levels in patients with vascular disease.14 Several studies have reported that folate administration reduces Hey concentrations of hyperhomocysteinaemic patients with vascular disease.15,16 Therefore, a defective function of other folate-dependent enzymes may be involved in hyper homocysteinaemia of vascular patients. However, the clinical benefits of this Hcy-Iowering therapy are unproven.
The remethylation of Hey occurs by transfer of a methyl group from 5-methyItetrahydrofoIate (Me-THF) via cobalamin to Hey. This reaction is catalysed by 5-methyltetrahydrofolate homocysteine methyltransferase (methionine synthase), which is probably present in all mammalian tissues, and requires cobalam in as a cofactor. The enzyme, betaine-homocysteine methyltransferase, can also remethylate Hey to methionine, but this enzyme is present only in the liver. Several studies have suggested that a defective methionine synthase (MS) could be a critical defect in folate-related NTDs.1'2'17,18 MS is essential for maintaining adequate intracellular methionine and tetrahydrofoiate pools, as well as for ensuring that the Hey concentration does not reach toxic levels. Since elevated H ey levels are observed not only in NTD patients and their parents, but also in patients with vascular diseases, both diseases could be caused by defect ive MS.
Recently, the human MS cDNA-sequence has been cloned19'20 and mutations causing the inborn error of metabolism cbIC have been described. 20, 21 The gene has been mapped to 1q43, near the telomere of chromosome 1, The human M S gene has an open reading frame of 3768 bases w hich encodes a protein of 1256 amino acids with a 5 5 % homology compared to E. coli MS. Although enzym ic studies have indicated a higher activity for M S in kidney, the RN A expression levels of M S seem to be similar in different tissues. 19 In order to study the postulated involvement of MS at the genomic level, we selected eight patients with mild hyperhomocysteinaemia: four NTD patients and four women with severe spiral arterial disease (SAD ) during their pregnancies. SAD causes infarction of the placenta, resulting in a stillborn or severely growth-retarded child, and is predominantly the result of spiral artery occlusion in the myome trium or decidua. Histological examination of the spiral arteries in SAD reveals one or more signs of vascülopathy, i.e. arteriosclerosis, narrowing, nec rosis and thrombosis. SAD is an occlusive arterial disease that is associated with elevated Hey levels,22 like most vascular diseases. By direct sequencing of the complete coding region of MS from eight hyper homocysteinaemic patients, we examined whether mutations in the MS gene were involved in these Hcy-related diseases.
Methods

Patients
Eight patients with mild hyperhomocysteinaemia (Hey levels above the normal range for their sex and age category),1 four NTD patients and four vascular patients who had a pregnancy complicated by SAD, were selected for direct sequencing of the cD N A of the M S gene. The elevated Hey levels were not due to the TT genotype for the 677C->T transition in M THFR, except patient SAD 4, who had a TT genotype but had very high Hey levels. The age, sex, folate and Hey data of these individuals are given in Table 1 . The normal ranges of plasma folate, red-cell folate and Hey are between 6-22 nmol/l; 213-817 nmol/l and 4.6-15 jumol/l, respectively.1
To examine whether the 2756A-»G mutation was associated with mild hyperhomocysteinaemia, or was a genetic risk factor for NTD or SAD , we studied the prevalence of this mutation among NTD patients and mothers with NTD-affected offspring, and patients who had suffered from SAD. The study group consisted of 69 mothers with a child with NTD (mean age 46, SD 12.6 years) and 56 NTD patients, mostly spina bifida, (mean age 21, SD 12.3 years).6-0 Furthermore, we studied 108 patients with SAD (mean age 34, SD 5.3 years). The diagnosis of SAD was established if the placenta was character ized by circumscribed areas of villous necrosis combined with a stillborn fetus or a severely growthretarded child, i.e. having a birth weight below the 10th percentile of gestational age. The population-based control group consisted of 364 unrelated Dutch individuals of either gender and no history of NTD or SAD (mean age 51, SD 12.4 years).0
Laboratory methods
Total homocysteine concentrations were measured in EDTA plasma. 23 Total RNA of NTD patients was extracted from EBV (Epstein Barr Virus) cell lines and the RN A of the vascular patients from lymphocytes isolated of w hole blood,24 and was stored as an ethanol precipit ate at -80°C. A 5 jag sample of RNA was reversetranscribed to cD N A in 1 h at 42°C with 200 units of Superscript!! reverse transcriptase (Life Technologies), using oligo(dT) and random hexanucleotides. A 2.5 )_lI aliquot of this first-strand cD N A was amplified by PCR. Amplifications w ere carried out in a total volum e of 100 jul, containing 100 ng forward and reverse primer, 200 |iM each dNTP, 10 mM Tris-HCl (pH 8.3), 50 mM KCI, 0.75-1.5 mM M gCl2 and 1 unit Taq polymerase (Life Technologies). Amplification parameters w ere as follows: 35 cycles of 92 °C/60 s (dénaturation), 54-64 °C/60 s (annealing) and 72°C/90 s (extension). The cycles were preceded by an initial dénaturation step of 2 min at 92 °C and were followed by a final extension of 7 min at 72 °C .
PCR and sequencing primers were designed based on the cD N A sequence.19 W e constructed 6 pairs of oligonucleotides (MS1-12), (Table 2 ). These primers were designed to generate overlapping fragments of 700-900 bp, covering the total cD N A sequence. These fragments were screened for the presence of mutations by direct sequencing; two forward and two reverse oligonucleotides were used to analyse each of the six fragments.
The sequence analysis was performed by auto mated sequencing (ABI Prism, model 377 version 2.1.2), using the ABI Prism Taq DyeDeoxy terminator cycle sequencing ready reaction kit (Perkin Elmer), according to the instructions of the manufacturer. D N A was isolated from whole blood and lympho cytes as described by M iller et a i25 and approxi mately 100 ng was used for PCR amplification. When w e tried to confirm the 2 7 5 6 A^C mutation on genomic D N A , w e observed that a large intron of over a 1000 bp was present in the genomic D N A at position 2775 of the cD N A. W e sequenced the intron with the oligonucleotides MS28 and MS29 and selected an intronic oligonucleotide (MS30), (Table 2) , to make screening for the 2756A-^G mutation on genomic D N A possible. The PCR for detection of this mutation on genomic D N A was carried out in a total volume of 50 jil, containing 50 ng of the MS28 and MS30 oligonucleotides (see Table 2 ), 200 (iM of each dNTP, 10m M Tris-HCI (pH 8.3), 50 mM KCI, 1.0 mM MgCl2 and '! unit Taq polymerase (Life Technologies). PCR parameters were as follows: an initial dénaturation step of 2 min at 92 °C , followed by 35 cycles of: 92 °C/60 s (dénatura tion), 56°C/60 s (annealing) and 72 °C/90 s (exten sion), and a final extension for 7 min at 72 °C The amplified PCR fragments were digested with the restriction enzyme Haelll to screen for the presence of the2756A-+ G mutation. An A A genotype resulted in an uncut fragment of 265 bp, whereas an AG genotype gave three fragments of 265, 180 and 85 bp, and a G G genotype showed two fragments of 180 and 85 bp.
Statistics
Odds ratios (O R) and 9 5 % Cls for the 2756A -»G mutation were calculated to estimate the relative risk of this mutation in NTD patients, their mothers and SAD patients. The Hey concentrations per MS geno type were expressed as means+ SD. Statistical signi ficance was tested by a paired W ilcoxon Rank Sum test p < 0*05 was considered statistically significant, all p values were two-tailed.
Results
The human M S gene was examined for involvem ent in mild hyperhomocysteinaemia observed in N TD and vascular diseases. To look for mutations in the coding region of MS, M S cD N A from 4 NTD patients and 4 patients with SAD with mildly elevated H ey levels, was screened by direct sequencing.
Total R N A of NTD patients was extracted from EBV cell lines, and that of the vascular patients from isolated lymphocytes. The isolated RNA was reversetranscribed to cD N A and amplified by PCR for direct sequencing analysis. RT-PCR of total lymphoblastoid and lymphocyte RNA yielded products of the expected size, indicating that M S is expressed in cultured lymphoblasts and lymphocytes.
By direct sequencing of the entire coding region of MS of the selected patients with mild hyperhomocyste inaemia, we observed three silent mutations in the cD N A of these individuals, see Table 3 . Furthermore, we identified an A->G transition at bp 2756, con verting an aspartic acid into a glycine (D919G). This mutation was present in two SAD patients and one NTD patient, in a heterozygous state in all. The observed nucleotide substitution creates a H aelll restriction site, which allowed the confirmation of the D919G mutation on genomic DNA.
To determine whether the 2756A-+G mutation was a risk factor for NTD offspring and vascular disease, we screened for its prevalence in the gen omic D NA of 56 NTD patients, 69 mothers of children with NTDs, 108 SAD patients and 364 Dutch controls. After amplification of the appropriate region of the genomic DNA by a PCR reaction using primers MS28 and MS30, the PCR fragment was digested with Haelll. The homozygous mutated G G genotype was present in only 1.8% of the N TD patients, 2 .9 % of their mothers, 2.8% of the SA D patients and 3 .3 % of the controls. Table 4 shows that the AG-genotype was fairly prevalent, that is in 2 5 % of the NTD patients, 2 7 .5 % of the mothers with NTD-affected offspring, 28.7% of the SA D patients and 25.8% of the controls. The frequency in the control group of the A-allele is 0.84 and of the G-allele 0.16. According to the Hardy-Weinberg equation the following genotype distribution was expected, AA genotype 70,6%; A G genotype 2 6 .9 % and G G genotype 2.6%, which is in agreement with the observed genotype distributions among the differ ent study populations, see Table 4 .
There was at most only a slightly increased prevalence of the G G and A G genotypes in N TD patients, their mothers, and SAD patients, indicating that this amino acid change is not a major (if any) risk factor for NTD or SAD. This is reflected in the calculated ORs of 0.5-1.1 for the G G and A G genotypes in SAD patients, NTD patients and their mothers ( Table 5 ). To examine whether the 2756A-+G mutation in M S was associated with mild hyperhomocysteinae mia, we determined the mean H ey levels of the different M S genotypes. The Hey levels of mothers with a NTD child with an A G genotype were elevated when compared with the Hey levels of mothers with an A A or G G genotype, but not significantly so. The Hey levels of NTD patients, patients with SAD and controls between the three M S genotypes did not differ, see Table 6 .
Discussion
By direct sequence analysis of the complete coding region of M S we observed four mutations (Table 3) . Three were silent mutations, and only one mutation, an A~*G substitution at bp 2756, resulted in an amino acid change, of an aspartic acid into a glycine (D919G). D919 corresponds to Q893 in E coli MS. This is at the penultimate position in a long helix that leads out of the cobalamin domain to the S-adenosylmethionine-binding domain in the highly Table 3 Sequence Plasma homocysteine concentrations are expressed as means ±SD, in jimol/l. NP, not possible, because n = l.
homologous bacterial M S. 26 Having the glycine res idue at this position, which is a strong helix breaker, versus aspartic acid which is a moderate helix maker, could have an effect on the secondary structure of the protein and therefore have functional con sequences. This 2756A->G transition has also been observed in cblG patients and controls in the study of Leclerc et a i20
A possible involvement of the D919G mutation in the risk for NTD and SAD was investigated by analysing the prevalence of the 2756A-»G mutation in the M S gene of NTD patients, mothers with NTD-affected offspring and patients that had suffered from SAD during their pregnancy. No significantly increased prevalence of G G and A G genotypes was present in NTD patients, their mothers or SAD patients when compared with the prevalence among controls, resulting in ORs of 0.5-1.1 for NTD patients, their mothers and patients with SAD (Tables 4 and 5), indicating that this amino acid change is not a major (if any) risk factor for NTD or SAD. The presence of the D919G mutation has also no effect on the Hey levels (Table 4 ). This suggests that the D919G mutation in the MS gene is a fairly prevalent, but probably benign polymorphism. Expression stud ies with the D919G mutation w ill resolve whether this polymorphism has a significant effect on MS function, as might have been expected from its postulated effect on helix formation.
The folate levels of mothers with NTD offspring are not deficient,11 suggesting that there are no major nutritional folate deficiencies. The 677C-VT mutation in the M TH FR gene can explain at most 27.4% of the protective effect of folate.7 Since folate adminis tration reduces the risk for N TD by at least 7 0 % or more,4,5 this implies that there may be other genetic defects present in the folate-related Hey metabolism that can be corrected by an additional folate intake.
In order to identify these candidate defective enzymes in the folate-dependent Hey metabolic pathway, we recently analysed the plasma cobala min, plasma and red cell folate, and plasma homo cysteine levels of NTD patients and their parents.11 W e observed, even after exclusion of those indi viduals homozygous for the 677C-»T mutation in the M THFR gene, significantly elevated Hey levels and decreased plasma folate levels in NTD patients and their parents. Plasma folate is mostly (80-90%) Me-THF, which is the circulating form of folate. Thus, a defective M S would not lead to decreased plasma folate levels, but rather increased plasma folate concentrations, since Me-THF is the substrate of MS in the remethylation of Hey to methionine. So, the results of our vitamin and Hey analyses of our NTD population11 are in agreement with the present sequencing results. Neither indicate a direct or significant role for MS in the aetiology of NTD. It is possible that other mutations in MS may have been missed, since we screened M S in only eight hyperhomocysteinaemic patients by direct sequen cing, However, if such mutations exist, they are unlikely to be present at high enough frequency to explain a significant proportion of the observed hyperhomocysteinaemia among NTD and vascular disease patients.
Since, the elevated Hey levels in patients with vascular disease, mothers of children with NTDs, or NTD patients, are probably not due to a decreased function of CS or MS, and only partly due to the 677C-*T mutation in the M THFR gene, other enzymes involved in the folate-dependent Hey meta bolism may be compromised. In our vitamin study, we observed significantly decreased plasma folate levels in NTD families.11 Decreased Me-THF levels have also been reported in patients with vascular disease,27,28 suggesting the presence of other muta tions present in M THFR or other enzymes in the folate metabolism involved in the synthesis of Me-THF. Such candidate enzymes (see Figure 1 ), leading to mild hyperhomocysteinaemia in NTD and vascular disease, include serine hydroxymethyltransferase, methylenetetrahydrofolate dehydro genase and the auxiliary redox proteins that regulate methionine synthase or MTHFR.
